Question Everything. See who's reporting it.

Dr. Reddy’s delays semaglutide supplies due to quality issue

Source: The Hindu

The story in brief

Dr. Reddy’s faced delays in semaglutide supplies due to quality issues, impacting availability. The company confirmed no safety risks and is investigating. Shares fell 5.24% to ₹1,278. The issue relates to semaglutide, the active ingredient in Wegovy and Ozempic. Dr. Reddy’s launched its generic injection Obeda and later a biosimilar tablet. It is developing the product in-house and committed to quality. The issue does not affect global regulatory filings.

3 outletsSee what the other 2 outlets said

NEWXFree on Android and iPhone. Open in NEWX